See pivotal and 5-year efficacy and safety data for VEMLIDY

Because it's the moments that matter—choose VEMLIDY for the long term

VEMLIDY offers proven efficacy and a well-established safety profile for adult chronic HBV patients with compensated liver disease—including treatment-naïve patients.1-5

VEMLIDY is proven in robust global clinical trials1-5

See pivotal and 5-year data

The 5-year data is not presented in the VEMLIDY label.

Watch hep B
experts discuss
the Simplified
Approach to
Hepatitis B

Learn how this approach may apply to your adult chronic hep B patients

View now

Choose VEMLIDY as a preferred first-line treatment option for
adults with chronic HBV, recommended in 5 guidelines/algorithms6-10

SABA 2022

Simplified Approach
Hepatitis B Algorithm

USTA 2021

United States Treatment

AATA 2018

Asian American
Treatment Algorithm

AASLD 2018

American Association for the
Study of Liver Diseases

EASL 2017

European Association for
the Study of the Liver

Help your patients save on prescription costs

Eligible commercially insured patients can save up to $6000 annually—with no monthly limit—with the VEMLIDY Co-pay Coupon Program.

*For commercially insured eligible patients only. Restrictions apply. Subject to change; click "See the details" below for full terms and conditions. This is not health insurance. Only accepted at participating pharmacies.

For your patients:
patients share
their stories

Share their journeys with your
patients, and download other
available patient resources

See more

VEMLIDY offers simple once-daily
dosing, taken with food1

VEMLIDY is a 25-mg pill that’s 8 mm in diameter. Pill image not to scale.

Close-up photo of a hand holding a VEMLIDY pill with GSI engraved on the surface



  • Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Warnings and Precautions

  • Risk of Development of HIV-1 Resistance in HBV/HIV-1 Coinfected Patients: Due to this risk, VEMLIDY alone should not be used for the treatment of HIV-1 infection. Safety and efficacy of VEMLIDY have not been established in HBV/HIV-1 coinfected patients. HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with VEMLIDY, and, if positive, an appropriate antiretroviral combination regimen that is recommended for HBV/HIV-1 coinfected patients should be used.
  • New Onset or Worsening Renal Impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with TAF-containing products. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue VEMLIDY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Monitor renal function in all patients – See Dosage and Administration.
  • Lactic Acidosis and Severe Hepatomegaly with Steatosis: Fatal cases have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (TDF). Discontinue VEMLIDY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse Reactions

Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 144 were headache, upper respiratory tract infection, abdominal pain, cough, back pain, arthralgia, fatigue, nausea, diarrhea, dyspepsia, and pyrexia.

Drug Interactions

  • Coadministration of VEMLIDY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and the risk of adverse reactions.
  • Coadministration of VEMLIDY is not recommended with the following: oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, or St. John’s wort. Such coadministration is expected to decrease the concentration of tenofovir alafenamide, reducing the therapeutic effect of VEMLIDY. Drugs that strongly affect P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) activity may lead to changes in VEMLIDY absorption.

Consult the full prescribing information for VEMLIDY for more information on potentially significant drug interactions, including clinical comments.

Dosage and Administration

  • Testing Prior to Initiation: HIV infection.
  • Prior to or When Initiating, and During Treatment: On a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.
  • Dosage in Adults: 1 tablet taken once daily with food.
  • Renal Impairment: Not recommended in patients with end stage renal disease (ESRD; eCrCl <15 mL/min) who are not receiving chronic hemodialysis; in patients on chronic hemodialysis, on hemodialysis days, administer VEMLIDY after completion of hemodialysis treatment.
  • Hepatic Impairment: Not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.


VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Please see full Prescribing Information for VEMLIDY, including BOXED WARNING.